Shots:

• The approval is based on two studies- PRONTO-T1D & PRONTO-T2D assessing fast-acting insulin lispro (URLi) vs Humalog both in combination with insulin glargine/ degludec in 1-222 & 673 patients with T1D & T2D respectively
• The PRONTO-T1D & PRONTO-T2D resulted in meeting 1EPs of non-inferior A1C reduction @26wks.- reduction in blood glucose spikes at both one and two hrs. following a test meal
• The fast-acting formulation of insulin lispro- currently being evaluated in adults with T1D & T2D. If approved- it will be commercialized under the trade name Liumjev in the EU

Click here ­to­ read full press release/ article 

 Ref: Eli Lilly | Image: Eli Lilly